Feasibility of Estimating the Prevalence and Management of Stage 4 CKD the Gard, France

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorCentre Hospitalier Universitaire de Nīmes

About this trial

The main objective of this study is to evaluate the feasibility of estimating the prevalence of stage 4 and 5 chronic kidney disease in the Gard department of France from data obtained via laboratory databases. To verifiy if the demand for care thus authenticated by laboratory tests is adapted to nephrology care delivery, as recommended by the French High Authority of Health (HAS), laboratory data will be compared with those of patients seen by nephrologists in the department.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

chronic kidney disease (stage >= 4)

Disqualifiers

None

Trial population

Persons with \>= stage 4 chronic kidney disease and residing in the Gard department of France.

Trial design

Design model

Ecologic or community

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

3,375 Participants
are grouped into 1 trial group
Group A: The study population

Trial outcomes

Primary outcomes

1

The prevalence of chronic kidney disease stage > = 4 in the Gard according to laboratory data (raw number)

Time frame
from baseline (day 0) to 12 months
2

The prevalence of chronic kidney disease stage > = 4 in the Gard according to laboratory data (%)

Time frame
from baseline (day 0) to 12 months

Secondary outcomes

1

The percentage of patients with CKD stage >= 4 correctly reported by participating nephrologists

Time frame
from baseline (day 0) to 12 months
2

For each nephrologist participating in the study, the % of patients with stage >=4 chronic kidney disease who are correctly declared

Time frame
from baseline (day 0) to 12 months
3

The % of patients with chronic kidney disease stage > = 4 in the Gard according to laboratory data and who are not seen by a nephrologist

Time frame
from baseline (day 0) to 12 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.